Glauprost, eye drops 0.005% 2.5ml 3 pcs.

Antiglaucoma drug.

The prostaglandin F2α analogue and a selective FP-receptor agonist.

Limits intraocular pressure by increasing outflow of aqueous humor, mainly through uveoscleral route and also through trabecular meshwork. It has no significant effect on aqueous humor production and does not affect the blood-ophthalmic barrier.

The decrease of intraocular pressure starts 3-4 hours after administration of the drug, the maximum effect is noted after 8-12 hours, the action lasts for at least 24 hours.

Indications

Active ingredient

Composition

1 ml – latanoprost 50 mcg

Ancillary substances:

desodium hydrophosphate dodecahydrate,

sodium dihydrophosphate dihydrate,

How to take, the dosage

In the conjunctival sac of the affected eye, 1 drop once daily, in the evening.

If a dose is missed, the next dose is not doubled and is given as usual.

Interaction

Pharmaceutically incompatible with eye drops containing thiomersal precipitate.

If combined therapy is prescribed, eye drops of different drugs should be administered at least 5 min apart.

The simultaneous instillation of two prostaglandin analogues may cause a paradoxical increase in intraocular pressure.

Special Instructions

Causes a gradual change in eye color by increasing the amount of brown pigment in the iris. This effect is predominantly seen in patients with mixed iris coloration, such as blue-brown, gray-brown, green-brown, or yellow-brown, due to increased melanin content in the stromal melanocytes of the iris. Brown pigmentation usually spreads concentrically around the pupil to the periphery of the iris of the eye, and the entire iris or parts of it may become more intense brown. If there is an intense change in ocular pigmentation, therapy should be discontinued.

In patients with uniformly blue, gray, green or brown colored eyes, changes in eye color after 2 years of use are very rare. The color change that develops may be irreversible. Patients should be informed of the possibility of eye color change before treatment.

The drug contains benzalkonium chloride which may be absorbed by contact lenses. Contact lenses should be removed before applying the eye drops; lenses should not be inserted until 15 minutes after application.

Latanoprost may cause gradual changes in eyelashes and down hair, such as lengthening, thickening, increasing pigmentation, increasing density, and changing the direction of eyelash growth. Eyelash changes are reversible and go away after treatment is discontinued.

In patients using drops in only one eye, heterochromia may develop.

Impact on driving and operating machinery

Patients who experience transient blurring of vision after use of eye drops are not recommended to drive vehicles or operate machinery until it is restored.

Contraindications

With caution:

Side effects

Eye irritation (burning sensation, feeling of sand in the eye, itching, tingling, and sensation of foreign body), blepharitis, conjunctival hyperemia, eye pain, increased iris pigmentation, transient pinpoint epithelial erosions, edema, corneal edema and erosions, conjunctivitis; lengthening, thickening, increase in number and pigmentation of eyelashes and downy hair, change in direction of eyelash growth, sometimes causing eye irritation, iritis/veitis, keratitis, macular edema (incl.including cystoid), blurred vision.

Dermatological reactions

Rash, darkening of the eyelid skin and local skin reactions from the eyelids.

Nervous system disorders

Dizziness , headache.

Respiratory system disorders

Bronchial asthma (including acute attacks or exacerbation of the disease in patients with a history of bronchial asthma), dyspnea.

Muscular system disorders

Muscle pain, joint pain.

Other

Nonspecific chest pain.

Overdose

Symptoms: irritation of the mucous membrane of the eye, hyperemia of the conjunctiva or episclera.

Treatment: symptomatic.

Pregnancy use

The drug Glauprost is contraindicated in children (under 18 years of age).

The use of Glauprost during pregnancy is only possible under medical supervision and only if the expected benefits to the mother outweigh the risk of possible side effects in the fetus.

Latanoprost and its metabolites can be excreted with breast milk.

Breastfeeding should be stopped if Glauprost must be prescribed during lactation.

Similarities